Lilly's Cyramza meets in Phase III for urothelial carcinoma

In May, Eli Lilly and Co. (NYSE:LLY) reported data from the Phase III RANGE trial in 531 patients with locally advanced, unresectable or metastatic urothelial carcinoma who progressed on or after platinum-based chemotherapy showing that IV Cyramza ramucirumab (IMC-1121B, LY3009806) plus docetaxel met the primary endpoint of improving progression-free survival (PFS) vs. placebo plus docetaxel.

The double-blind, international trial's secondary endpoints include overall survival (OS), objective response rate (ORR), disease control rate (DCR) and duration of response. Final OS data are expected in mid-2018...